Press Release
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85% Crofelemer, approved by the FDA under the brand name Mytesi® for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS Crofelemer could have a significant supportive impact on GLP-1 therapies, one of the fastest growing classes of drugs, estimated to be a $56 billion global market in 2025 and projected to grow at a CAGR of 21% to $322 billion 20341 Read More
Press Release
Integrative Providers Association (IPA) and Compassion Center Call on U.S. Senate to Fast Track Robert F. Kennedy Jr.’s Confirmation
Integrative Providers Association, a 501(c)(6) Professional Membership Organization Speaking on Behalf of Over 14 Million Integrative Healthcare Practitioners, and the Compassion Center, Proudly Champions "Secretary Kennedy" as a Maverick in Holistic Health and Nutrition, Urging Our U.S. Senators to Expedite Confirmation In The Name of Wellness. IPA Members Support Robert F. Kennedy's Agenda to Redirect Healthcare In The United States Read More
Press Release
Compassion Center, Coalition for Patients' Rights, and Integrative Providers Association Urge Senate to Confirm RFK Jr. as Secretary of Health and Human Services
UNITED SUPPORT FOR RFK JR. AT HHS: The Compassion Center, Coalition for Patients' Rights, and Integrative Providers Association urge the Senate to confirm Robert F. Kennedy Jr. as Secretary of Health and Human Services. Citing his decades-long advocacy for patient rights, environmental responsibility, and integrative care, they see a transformative opportunity to restore trust, champion preventative solutions, and reduce chronic disease. They call for swift action to usher in an era of holistic, compassion-driven leadership. We stand ready. Read More
Press Release
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical trial in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - Read More
Press Release
